Future studies employing phospho-specific assays and pathway-level analyses will be essential to dissect the full spectrum of STAT3-mediated signaling in ALL and to further validate the mechanistic synergy observed in our combination strategy. The gene discussed is STAT3; the disease is acute lymphoblastic leukemia.